NCT00669890View on ClinicalTrials.gov

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2013

Conditions
Acute Myeloid LeukemiaJuvenile Myelomonocytic LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Gemtuzumab Ozogamicin

Dose Escalation

DRUG

Busulfan

Conditioning Regimen

DRUG

Cyclophosphamide

Conditioning Regimen

DRUG

Thymoglobulin

(Unrelated Donors only)

DRUG

Tacrolimus

GVHD Prophylaxis

DRUG

Mycophenolate Mofetil

GVHD Prophylaxis

DRUG

Methotrexate

GVHD Prophylaxis

Trial Locations (1)

10032

Morgan Stanley Children's Hospital of NYP, New York

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER

NCT00669890 - Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | Biotech Hunter | Biotech Hunter